{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu J"],"funding":["Kashi Regional Science and Technology Program Projects","the Hospital Scientific research project of the First People's Hospital of Kashi","Dedicated funding for stem cell research project of the First People's Hospital of Kashi"],"pagination":["28339"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12322009"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Pulmonary fibrosis (PF) is a progressive, irreversible disease with limited effective treatments. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) have recently shown promise in PF therapy. This study evaluated the therapeutic effects and mechanisms of UC-MSCs combined with pirfenidone (PFD) in a bleomycin-induced PF model. C57BL/6 mice were divided into nine groups: control, model, PFD (100 mg/kg), UC-MSCs (0.5 × 10<sup>6</sup>, 1.0 × 10<sup>6</sup>, and 2.0 × 10<sup>6</sup> cells per animal), and PFD (100 mg/kg) + UC-MSCs (0.5 × 10<sup>6</sup>, 1.0 × 10<sup>6</sup>, and 2.0 × 10<sup>6</sup> cells per animal). The model was established by intratracheal bleomycin instillation. PFD was administered intraperitoneally twice daily from day 4 to 21 in the PFD and PFD + UC-MSCs grou"],"journal":["Scientific reports"],"pubmed_title":["Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis."],"pmcid":["PMC12322009"],"funding_grant_id":["2023-13","KDYY202312","KS2023012","KS2022033"],"pubmed_authors":["Abudureheman Z","Zou X","Zhong X","Xue L","Li L","Xu J","Gong H"],"additional_accession":[]},"is_claimable":false,"name":"Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis.","description":"Pulmonary fibrosis (PF) is a progressive, irreversible disease with limited effective treatments. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) have recently shown promise in PF therapy. This study evaluated the therapeutic effects and mechanisms of UC-MSCs combined with pirfenidone (PFD) in a bleomycin-induced PF model. C57BL/6 mice were divided into nine groups: control, model, PFD (100 mg/kg), UC-MSCs (0.5 × 10<sup>6</sup>, 1.0 × 10<sup>6</sup>, and 2.0 × 10<sup>6</sup> cells per animal), and PFD (100 mg/kg) + UC-MSCs (0.5 × 10<sup>6</sup>, 1.0 × 10<sup>6</sup>, and 2.0 × 10<sup>6</sup> cells per animal). The model was established by intratracheal bleomycin instillation. PFD was administered intraperitoneally twice daily from day 4 to 21 in the PFD and PFD + UC-MSCs grou","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-08T23:20:28.703Z","creation":"2026-04-07T13:17:42.582Z"},"accession":"S-EPMC12322009","cross_references":{"pubmed":["40760158"],"doi":["10.1038/s41598-025-14286-4"]}}